Sofinnova Investments, Inc.
Long book
$2.00B
Q1 2026
Positions
61
Top-10 weight
55%
concentration
Last quarter
+16.6%
SPY +14.8%
Turnover
43%
of book per quarter
Strategy in plain words
auto-generated from filingsSofinnova Investments, Inc. is a diversified fundamental manager, specialised in healthcare (100% of the long book), running a $2.00B US long book across 61 positions.
The portfolio is concentrated: the top 10 names carry 55% of the portfolio. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: NATERA INC, BRISTOL-MYERS SQUIBB CO, JAZZ PHARMACEUTICALS PLC, VERA THERAPEUTICS INC, UNITED THERAPEUTICS CORP.
Over the last 9 quarters its long book ran on average 3.1pp per quarter ahead of the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+2.6%
Q2 2024
+3.6%
Q3 2024
-7.1%
Q4 2024
-10.8%
Q1 2025
+5.9%
Q2 2025
+22.3%
Q3 2025
+35.8%
Q4 2025
-0.8%
Q1 2026
+16.6%
Sector allocation
Healthcare 100%
Materials 0%
Other 0%
Long book by quarter
What does Sofinnova Investments, own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| NTRA NATERA INC | Healthcare | 1.6M | $310.0M | 15.5% | Held |
| BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 2.0M | $120.6M | 6.0% | +31.4% |
| JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 598.3K | $113.1M | 5.7% | -37.7% |
| VERA VERA THERAPEUTICS INC | Healthcare | 2.8M | $112.4M | 5.6% | Held |
| UTHR UNITED THERAPEUTICS CORP | Healthcare | 160.1K | $94.9M | 4.8% | +1.5% |
| AZN ASTRAZENECA PLC | Healthcare | 456.0K | $89.9M | 4.5% | New |
| COGT COGENT BIOSCIENCES INC | Healthcare | 2.1M | $81.4M | 4.1% | +7.1% |
| RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 3.1M | $65.9M | 3.3% | +3676.6% |
| RAPP RAPPORT THERAPEUTICS INC | Healthcare | 1.9M | $59.6M | 3.0% | Held |
| INSM INSMED INC | Healthcare | 346.1K | $56.6M | 2.8% | +120.7% |
| ALC ALCON INC | Healthcare | 730.0K | $55.0M | 2.8% | +119.5% |
| SUPN SUPERNUS PHARMACEUTICALS INC | Healthcare | 954.3K | $49.3M | 2.5% | +72.5% |
| BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 782.0K | $44.2M | 2.2% | +12.2% |
| BIIB BIOGEN INC | Healthcare | 229.5K | $42.1M | 2.1% | New |
| CELC CELCUITY INC | Healthcare | 366.2K | $41.8M | 2.1% | +22.3% |
| BIOA BIOAGE LABS INC | Healthcare | 2.3M | $40.1M | 2.0% | Held |
| RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 450.1K | $39.1M | 2.0% | +65.8% |
| AVBP ARRIVENT BIOPHARMA INC | Healthcare | 1.7M | $39.1M | 2.0% | Held |
| IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.1M | $37.7M | 1.9% | +27.9% |
| IMNM IMMUNOME INC | Healthcare | 1.7M | $37.2M | 1.9% | +5.2% |
| NKTR NEKTAR THERAPEUTICS | Healthcare | 509.5K | $36.7M | 1.8% | +16.2% |
| AXSM AXSOME THERAPEUTICS INC | Healthcare | 212.7K | $36.0M | 1.8% | +1634.4% |
| IMTX IMMATICS NV | Healthcare | 3.6M | $35.7M | 1.8% | +5.7% |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 409.2K | $30.4M | 1.5% | -43.2% |
| DYN DYNE THERAPEUTICS INC | Healthcare | 1.6M | $29.6M | 1.5% | -27.5% |
| INBX INHIBRX BIOSCIENCES INC | Healthcare | 406.0K | $27.3M | 1.4% | -10.7% |
| DXCM DEXCOM INC | Healthcare | 393.6K | $24.7M | 1.2% | +4.1% |
| PHVS PHARVARIS NV | Healthcare | 818.3K | $23.1M | 1.2% | +9.8% |
| PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 63.7K | $20.5M | 1.0% | -49.3% |
| RCUS ARCUS BIOSCIENCES INC | Healthcare | 923.1K | $19.9M | 1.0% | -15.8% |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 305.2K | $17.7M | 0.9% | +409.5% |
| SYK STRYKER CORP | Healthcare | 44.5K | $14.6M | 0.7% | New |
| ANAB ANAPTYSBIO INC | Healthcare | 248.3K | $13.8M | 0.7% | -13.7% |
| ROIV ROIVANT SCIENCES LTD | Healthcare | 478.0K | $13.2M | 0.7% | -34.9% |
| EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 386.5K | $12.2M | 0.6% | -11.7% |
| CMPX COMPASS THERAPEUTICS INC | Healthcare | 2.1M | $10.9M | 0.5% | -38.9% |
| ORIC ORIC PHARMACEUTICALS INC | Healthcare | 679.6K | $8.6M | 0.4% | New |
| TNGX TANGO THERAPEUTICS INC | Healthcare | 395.1K | $8.3M | 0.4% | New |
| TYRA TYRA BIOSCIENCES INC | Healthcare | 204.0K | $7.8M | 0.4% | New |
| AXGN AXOGEN INC | Healthcare | 210.7K | $7.0M | 0.3% | New |
| DFTX DEFINIUM THERAPEUTICS INC | Materials | 344.2K | $6.5M | 0.3% | New |
| CYTK CYTOKINETICS INC | Healthcare | 91.8K | $6.0M | 0.3% | New |
| IRON DISC MEDICINE INC | Healthcare | 78.3K | $5.0M | 0.3% | -29.4% |
| MANE VERADERMICS INC | Healthcare | 73.3K | $4.6M | 0.2% | New |
| HRMY HARMONY BIOSCIENCES HOLDINGS | Healthcare | 152.7K | $4.3M | 0.2% | New |
| PCVX VAXCYTE INC | Healthcare | 50.6K | $2.9M | 0.1% | New |
| MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 27.6K | $2.5M | 0.1% | +19.4% |
| NXTC NEXTCURE INC | Healthcare | 222.7K | $2.4M | 0.1% | Held |
| SVRA SAVARA INC | Healthcare | 364.8K | $2.0M | 0.1% | +19.7% |
| ESTA ESTABLISHMENT LABS HOLDINGS | Healthcare | 33.9K | $1.9M | 0.1% | +19.6% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 75 | $2.63B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 60 | $2.32B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 62 | $1.83B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 63 | $1.64B | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 65 | $1.53B | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 61 | $1.37B | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 13, 2024 | 62 | $1.26B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 9, 2024 | 82 | $1.92B | canonical | SEC ↗ |
| Q1 2024 | 13F-HR/ARESTATEMENT | Aug 14, 2024 | 74 | $1.80B | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 74 | $1.80B | SEC ↗ |